ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

ClinicalTrials.gov ID: NCT06144840

Public ClinicalTrials.gov record NCT06144840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Study identification

NCT ID
NCT06144840
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Enrollment
165 participants

Conditions and interventions

Interventions

  • Dersimelagon Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2023
Primary completion
Apr 13, 2026
Completion
May 31, 2026
Last update posted
May 7, 2026

2023 – 2026

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Marvel Clinical Research, LLC Huntington Beach California 92647
University of California at San Francisco San Francisco California 94143
University Of Miami School Of Medicine, Center For Liver Diseases Miami Florida 33136
MGH Boston Massachusetts 02129
MetroBoston Clinical Partners, LLC Brighton Massachusetts 02135-3511
Henry Ford Health System Detroit Michigan 48202
Kansas City Research Institute Kansas City Missouri 64131
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH) New York New York 10029-0311
Wake Forest University Baptist Health Winston-Salem North Carolina 27103
Remington-Davis Clinical Research Columbus Ohio 43215
Einstein Medical Center (EMC) Philadelphia Pennsylvania 19141
The University of Texas Medical Branch (UTMB) Galveston Texas 77555-0342
University of Washington Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06144840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06144840 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →